查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108261

2035年前次世代定序市場分析和預測：按類型、產品類型、服務、技術、組件、應用、流程、最終用戶和解決方案。

Next Generation Sequencing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球次世代定序市場預計將從2025年的161億美元成長到2035年的461億美元，複合年成長率（CAGR）為11.1%。次世代定序市場呈現中等程度的整合結構，定序服務和定序平台佔了主要細分市場，這主要得益於臨床診斷、腫瘤學、藥物研發和基因組學研究等領域對定序技術的日益成長的需求。定序成本的下降、技術的進步以及對精準醫療需求的成長是推動該市場發展的主要因素。市場競爭依然激烈，Illumina、Thermo Fisher Scientific和華大基因等領導企業專注於創新、夥伴關係和產品組合的拓展。例如，Illumina於2025年1月宣布與NVIDIA合作，將定序技術與人工智慧工具結合，以推動多體學資料分析和精準醫療領域的應用。

按類型分類，全基因測序組定序在2025年次世代定序市場中佔主導地位。這是因為全基因組定序能夠透過分析生物體的整個DNA序列提供全面的基因組資訊。由於其能夠產生高解析度數據，全基因測序被廣泛應用於臨床研究、罕見疾病診斷、精準醫療、腫瘤研究和群體基因組學等領域。定序成本的下降、生物資訊學平台的改進以及對大規模基因組舉措投資的增加，都推動了這一領域的發展。學術機構、製藥公司和醫療保健提供者擴大採用全基因組定序來識別基因變異並支持個人化治療策略，這進一步鞏固了其市場主導地位。

市場區隔
類型 全基因測序、標靶定序、EXOME定序、RNA定序、從頭定序、表觀表觀基因學、宏總體基因體學等。
產品 耗材、設備、軟體及其他
服務 定序服務、數據分析服務等。
科技 合成定定序、離子和半導體定序、單分子即時定序、奈米孔定序等。
成分 樣品製備、定序、數據分析及其他相關任務。
目的 臨床研究、腫瘤學、生殖醫學、農業基因體學、法醫學、藥物發現等。
過程 樣品製備、定序、資料處理及其他相關任務。
最終用戶 學術和研究機構、製藥和生物技術公司、醫院和診所等。
解決方案 內部實施、外包和其他

按應用領域分類，腫瘤學領域預計將在預測期內實現最快成長，這主要得益於NGS技術在癌症診斷、生物標記識別和標靶治療研發中日益廣泛的應用。 NGS能夠對腫瘤基因組進行全面分析，幫助臨床醫生識別具有治療意義的突變並選擇個人化治療方案。癌症發病率的上升、精準腫瘤學計畫的擴展以及伴隨診斷的日益普及正在加速該領域的成長。此外，定序公司與製藥公司在癌症藥物研發方面的合作，以及液態生物檢體和基於基因組的癌症監測技術的進步，預計將進一步推動該領域的快速擴張。

區域概覽

2025年，北美在次世代定序（NGS）市場佔領先地位，這得益於其先進的醫療基礎設施、強大的基因組學研究能力以及製藥公司、生物技術公司和學術機構的大量投資。美國仍然是最大的貢獻者，NGS在腫瘤學、精準醫療、基因診斷和藥物研發等領域得到了廣泛應用。領先的定序技術供應商、完善的研究網路、有利的保險報銷機制以及政府對基因組學舉措的持續資助，進一步鞏固了該地區的需求。此外，NGS在臨床工作流程和個人化醫療計畫中的日益普及，也進一步鞏固了北美的主導地位。

預計在預測期內，亞太地區將成為次世代定序(NGS) 市場成長最快的地區，這主要得益於醫療保健領域投資的增加、生物技術生態系統的擴張以及基因組技術的日益普及。中國、日本和印度等國家在精準醫療、癌症基因組學和農業基因組學等應用領域正經歷快速發展。政府主導的基因組學舉措、不斷擴大的研究合作以及對定序基礎設施投資的增加，正在加速全部區域市場的擴張。此外，慢性病盛行率的上升、醫療保健服務的改善以及本土定序公司的湧現，也為亞洲新興經濟體的 NGS 應用創造了巨大的機會。

主要趨勢和促進因素

人工智慧（AI）與先進生物資訊學的融合：

次世代定序(NGS) 市場正日益廣泛地採用人工智慧 (AI)、機器學習和先進的生物資訊解決方案，以增強基因組數據的分析和解讀。隨著 NGS 平台產生大量複雜的定序數據，AI 驅動的工具正在提高突變檢測、基因組註釋和預測分析的準確性，從而實現更快、更精準的洞察。這些進步透過簡化工作流程和降低分析複雜性，為臨床診斷、藥物研發和精準醫療等領域的應用提供了支援。 AI 與 NGS 技術的持續整合有望加速創新，並擴大定序解決方案在醫療和研究領域的應用。

精準醫療和基因組診斷的廣泛應用：

精準醫療和基因組診斷的日益普及是推動次世代定序(NGS) 市場成長要素。 NGS 能夠對基因變異進行全面分析，從而支持個人化治療策略、癌症譜分析、罕見疾病診斷和藥物基因體學領域的應用。醫療機構和製藥公司正擴大利用定序技術來改善治療效果並加速標靶藥物的研發。慢性病盛行率的上升、基因組研究計畫投入的增加以及基於定序的診斷方法加速融入臨床工作流程，都進一步推動了市場擴張。向個人化醫療的轉變持續催生全球對先進 NGS 解決方案的強勁需求。

目錄

第1章：摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 全基因測序
    • 標靶定序
    • EXOME定序
    • RNA定序
    • 從頭定序
    • 表觀基因
    • 總體基因體學
    • 其他
  • 市場規模及預測：依產品分類
    • 消耗品
    • 裝置
    • 軟體
    • 其他
  • 市場規模及預測：依服務分類
    • 定序服務
    • 數據分析服務
    • 其他
  • 市場規模及預測：依技術分類
    • 合成定序法
    • 離子半導體定序
    • 單分子即時定序
    • 奈米孔定序
    • 其他
  • 市場規模及預測：依應用領域分類
    • 臨床試驗
    • 腫瘤學
    • 生殖健康
    • 農業基因組學
    • 法醫學
    • 藥物發現
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 學術和研究機構
    • 製藥和生物技術公司
    • 醫院和診所
    • 其他
  • 市場規模及預測：依組件分類
    • 樣品製備
    • 定序
    • 數據分析
    • 其他
  • 市場規模及預測：依製程分類
    • 圖書館調整
    • 定序
    • 資料處理
    • 其他
  • 市場規模及預測：按解決方案分類
    • 內部
    • 外包
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Illumina
  • Thermo Fisher Scientific
  • Roche
  • Qiagen
  • Agilent Technologies
  • Pacific Biosciences
  • Oxford Nanopore Technologies
  • BGI Genomics
  • PerkinElmer
  • Bio-Rad Laboratories
  • Genewiz
  • Takara Bio
  • 10x Genomics
  • F. Hoffmann-La Roche
  • Eurofins Scientific
  • Macrogen
  • Genomatix
  • GATC Biotech
  • LGC Biosearch Technologies
  • Nugen Technologies

第9章 關於我們

簡介目錄
Product Code: GIS10518

The global Next Generation Sequencing Market is projected to grow from $16.1 billion in 2025 to $46.1 billion by 2035, at a compound annual growth rate (CAGR) of 11.1%. The Next Generation Sequencing Market is characterized by a moderately consolidated structure, with sequencing services and sequencing platforms representing the leading segments due to increasing adoption across clinical diagnostics, oncology, drug discovery, and genomic research. The market is driven by declining sequencing costs, technological advancements, and rising demand for precision medicine. Competitive intensity remains high, with major players such as Illumina, Thermo Fisher Scientific, and BGI Group focusing on innovation, partnerships, and portfolio expansion. For instance, in January 2025, Illumina announced a collaboration with NVIDIA to combine sequencing technologies with AI tools for advancing multiomic data analysis and precision health applications.

Based on Type, the Whole Genome Sequencing segment dominated the Next Generation Sequencing Market in 2025, owing to its ability to provide comprehensive genomic insights by analyzing the complete DNA sequence of an organism. Whole genome sequencing is widely adopted across clinical research, rare disease diagnosis, precision medicine, oncology studies, and population genomics due to its high-resolution data generation capability. The segment benefits from declining sequencing costs, improved bioinformatics platforms, and increasing investments in large-scale genomic initiatives. Growing adoption among academic institutions, pharmaceutical companies, and healthcare providers for identifying genetic variations and supporting personalized treatment strategies further reinforces its leading position in the market.

Market Segmentation
TypeWhole Genome Sequencing, Targeted Sequencing, Exome Sequencing, RNA Sequencing, De Novo Sequencing, Epigenomics, Metagenomics, Others
ProductConsumables, Instruments, Software, Others
ServicesSequencing Services, Data Analysis Services, Others
TechnologySequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Others
ComponentSample Preparation, Sequencing, Data Analysis, Others
ApplicationClinical Investigation, Oncology, Reproductive Health, Agrigenomics, Forensics, Drug Discovery, Others
ProcessLibrary Preparation, Sequencing, Data Processing, Others
End UserAcademic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others
SolutionsIn-House, Outsourced, Others

Based on Application, the Oncology segment is expected to register the fastest growth during the forecast period, driven by the increasing adoption of NGS technologies in cancer diagnosis, biomarker identification, and targeted therapy development. NGS enables comprehensive profiling of tumor genomes, helping clinicians identify actionable mutations and select personalized treatment approaches. The rising prevalence of cancer, expansion of precision oncology programs, and growing use of companion diagnostics are accelerating segment growth. Additionally, collaborations between sequencing companies and pharmaceutical firms for oncology drug development, along with advancements in liquid biopsy and genomic-based cancer monitoring, are expected to further support the rapid expansion of this segment.

Geographical Overview

North America dominated the Next Generation Sequencing (NGS) Market in 2025, supported by advanced healthcare infrastructure, strong genomic research capabilities, and significant investments from pharmaceutical, biotechnology, and academic institutions. The United States remains the leading contributor due to widespread adoption of NGS in oncology, precision medicine, genetic diagnostics, and drug discovery applications. The presence of major sequencing technology providers, well-established research networks, favorable reimbursement frameworks, and continuous government funding for genomics initiatives further strengthens regional demand. Additionally, increasing integration of NGS into clinical workflows and personalized healthcare programs continues to reinforce North America's leading position.

Asia-Pacific is expected to register the fastest growth in the Next Generation Sequencing (NGS) Market during the forecast period, driven by increasing healthcare investments, expanding biotechnology ecosystems, and rising adoption of genomic technologies. Countries such as China, Japan, and India are witnessing rapid development in precision medicine, cancer genomics, and agricultural genomics applications. Government-led genome initiatives, growing research collaborations, and increasing investments in sequencing infrastructure are accelerating market expansion across the region. Furthermore, the rising prevalence of chronic diseases, improving healthcare access, and the growing presence of domestic sequencing companies are creating significant opportunities for NGS adoption in emerging Asian economies.

Key Trends and Drivers

Integration of Artificial Intelligence and Advanced Bioinformatics:

The Next Generation Sequencing (NGS) Market is increasingly adopting artificial intelligence (AI), machine learning, and advanced bioinformatics solutions to enhance genomic data analysis and interpretation. As NGS platforms generate large volumes of complex sequencing data, AI-driven tools are improving variant detection, genome annotation, and predictive analytics, enabling faster and more accurate insights. These advancements are supporting applications in clinical diagnostics, drug discovery, and precision medicine by improving workflow efficiency and reducing analysis complexity. The continued integration of AI with NGS technologies is expected to accelerate innovation and expand the adoption of sequencing solutions across healthcare and research sectors.

Growing Adoption of Precision Medicine and Genomic Diagnostics:

The increasing adoption of precision medicine and genomic diagnostics is a major growth driver for the Next Generation Sequencing (NGS) Market. NGS enables comprehensive analysis of genetic variations, supporting personalized treatment strategies, cancer profiling, rare disease diagnosis, and pharmacogenomics applications. Healthcare providers and pharmaceutical companies are increasingly leveraging sequencing technologies to improve treatment outcomes and accelerate targeted drug development. Rising prevalence of chronic diseases, growing investments in genomic research programs, and increasing integration of sequencing-based diagnostics into clinical workflows are further supporting market expansion. The shift toward personalized healthcare continues to create strong demand for advanced NGS solutions globally.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Whole Genome Sequencing
    • 4.1.2 Targeted Sequencing
    • 4.1.3 Exome Sequencing
    • 4.1.4 RNA Sequencing
    • 4.1.5 De Novo Sequencing
    • 4.1.6 Epigenomics
    • 4.1.7 Metagenomics
    • 4.1.8 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Consumables
    • 4.2.2 Instruments
    • 4.2.3 Software
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Sequencing Services
    • 4.3.2 Data Analysis Services
    • 4.3.3 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Sequencing by Synthesis
    • 4.4.2 Ion Semiconductor Sequencing
    • 4.4.3 Single-Molecule Real-Time Sequencing
    • 4.4.4 Nanopore Sequencing
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Clinical Investigation
    • 4.5.2 Oncology
    • 4.5.3 Reproductive Health
    • 4.5.4 Agrigenomics
    • 4.5.5 Forensics
    • 4.5.6 Drug Discovery
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Academic & Research Institutions
    • 4.6.2 Pharmaceutical & Biotechnology Companies
    • 4.6.3 Hospitals & Clinics
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Sample Preparation
    • 4.7.2 Sequencing
    • 4.7.3 Data Analysis
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Library Preparation
    • 4.8.2 Sequencing
    • 4.8.3 Data Processing
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 In-House
    • 4.9.2 Outsourced
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Roche
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Qiagen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Agilent Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Pacific Biosciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Oxford Nanopore Technologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 BGI Genomics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 PerkinElmer
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bio-Rad Laboratories
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Genewiz
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Takara Bio
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 10x Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 F. Hoffmann-La Roche
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Eurofins Scientific
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Macrogen
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Genomatix
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 GATC Biotech
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 LGC Biosearch Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Nugen Technologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us